What does Puriblood Medical Co., Ltd. do?

Puriblood Medical Co., Ltd. (6847.TWO) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6847.TWO's market cap?

Puriblood Medical Co., Ltd. (6847.TWO) has a market capitalization of approximately $1.09 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6847.TWO pay a dividend?

No — Puriblood Medical Co., Ltd. (6847.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6847.TWO profitable?

Puriblood Medical Co., Ltd. (6847.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6847.TWO

Puriblood Medical Co., Ltd.

TWO·Medical, Diagnostics & Research · Healthcare

NT$76.50NT$0.50−0.65%

Market capNT$1.09B·Aug 26 6:57 AM UTC

Price Chart

NT$76.50−NT$0.50 (−0.65%)today

−40.47%CAGR −10.23%

Select date range

FromTo

Nov 5, 2021Nov 5, 2021 → Aug 26, 2026· 4.8 yrsAug 26, 2026

Key Metrics

6847.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$80.54M

Net Income−NT$55.81M

Net Margin−69.3%

Operating Cash Flow−NT$32.27M

Capital ExpendituresNT$386.00K

Free Cash Flow−NT$32.66M

Return on Equity−51.0%

Return on Invested Capital−15.6%

Net DebtNT$7.68M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6847.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6847.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6847.TWO and 80,000+ other tickers.

About Puriblood Medical Co., Ltd.

Puriblood Medical Co., Ltd., based in Hsinchu City, Taiwan, and established in 2016, specializes in manufacturing and distributing advanced solutions for blood component separation. The company's diverse product portfolio features filters designed for leukoreduction in various blood products, including red blood cells, platelets, and whole blood. They also provide immediate filtration systems for whole blood, alongside Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. A key innovation from Puriblood Medical is its proprietary P-Tex Technology, which leverages a bio-inspired molecular design based on a zwitterionic copolymer structure.

CEO: Luke Chen
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: TWO
Employees: 38
Website: www.puriblood.com

Peers

Peers Tab

4188.TWO

AmCad BioMed Corporation

Cap

NT$924.7M

4139.TWO

Ma Kuang Healthcare Holding Limited

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6847.TWO

What does Puriblood Medical Co., Ltd. do?: Puriblood Medical Co., Ltd. (6847.TWO) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6847.TWO's market cap?: Puriblood Medical Co., Ltd. (6847.TWO) has a market capitalization of approximately $1.09 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6847.TWO pay a dividend?: No — Puriblood Medical Co., Ltd. (6847.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6847.TWO profitable?: Puriblood Medical Co., Ltd. (6847.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.